Ramadevi Subramani Reddy | Cancer Biology | Research Excellence Award

Dr. Ramadevi Subramani Reddy | Cancer Biology | Research Excellence Award

Associate Professor | Texas Tech University Health Sciences Center El Paso | United States

Dr. Ramadevi Subramani Reddy is an Associate Professor at Texas Tech University Health Sciences Center El Paso and a researcher in Cancer Biology with extensive expertise in molecular and translational oncology. She holds advanced training in biochemistry and cancer biology, with doctoral specialization in cancer-related cellular mechanisms, including differentiation, cell cycle regulation, and apoptosis. Her professional experience spans progressive research roles from competitive fellowships to senior research and faculty positions, demonstrating sustained leadership in funded cancer research programs. Her work focuses on molecular signaling pathways, inflammation-mediated cancer progression, and translational strategies for cancer prevention and therapy, resulting in a strong body of peer-reviewed publications with significant citation impact. Dr Reddy has contributed to multidisciplinary research initiatives, mentored trainees, and supported collaborative cancer research efforts. Her career is distinguished by nationally and internationally funded fellowships and research awards that recognize her scientific rigor, consistency, and impact in advancing cancer biology research.

Citation Metrics (Google Scholar)

1732
1200
600
300
0

1732

34

24

Citations

Documents

h-index

Milad Shirvaliloo | Cancer Epigenetics | Best Researcher Award 

Dr. Milad Shirvaliloo | Cancer Epigenetics | Best Researcher Award 

Research Associate | Iran University of Medical Sciences | Iran

Dr. Milad Shirvaliloo is an accomplished physician–researcher specializing in epigenetics with a focus on cancer and pulmonary medicine. Holding a Doctor of Medicine and a Master of Business Administration in Health Sciences, he combines clinical expertise with research innovation to advance precision medicine. As a Postgraduate Researcher at the Finetech in Medicine Research Center, he leads studies on nanoparticle-based therapeutic interventions and their effects on histone acetylation in cancer. Dr. Shirvaliloo has authored more than forty peer-reviewed publications and a book chapter, contributing extensively to understanding molecular and epigenetic mechanisms in disease pathogenesis. His scholarly output includes first-author and single-author papers in leading journals, where he explores the roles of histone modifications, long noncoding RNAs, and nanobiosensor technologies in diagnostics and therapeutics. He has demonstrated academic leadership as an Editorial Board Member for Epigenomics and Molecular and Cellular Biochemistry and has served as a peer reviewer for over sixty high-impact journals. Recognized for his scientific excellence and editorial contributions, he has received the Best Researcher Award for his outstanding achievements in biomedical science. His ongoing work reflects a strong commitment to translational research, interdisciplinary collaboration, and mentorship of emerging scientists. With a clear vision for integrating molecular biology, nanotechnology, and clinical application, Dr. Shirvaliloo exemplifies the future of innovative medical research and continues to make significant contributions to global health advancement.

Profiles: Google Scholar | Scopus | ORCID

Featured Publications

1. Heris, R. M., Shirvaliloo, M., Abbaspour-Aghdam, S., Hazrati, A., Shariati, A., & others. (2022). The potential use of mesenchymal stem cells and their exosomes in Parkinson’s disease treatment. Stem Cell Research & Therapy, 13(1), 371.

2. Sheervalilou, R., Shirvaliloo, M., Dadashzadeh, N., Shirvalilou, S., Shahraki, O., & others. (2020). COVID‐19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019‐nCoV disease. Journal of Cellular Physiology, 235(12), 8873–8924.

3. Aghbash, P. S., Eslami, N., Shirvaliloo, M., & Baghi, H. B. (2021). Viral coinfections in COVID‐19. Journal of Medical Virology, 93(9), 5310–5322.

4. Shirvalilou, S., Khoei, S., Esfahani, A. J., Kamali, M., Shirvaliloo, M., & others. (2021). Magnetic hyperthermia as an adjuvant cancer therapy in combination with radiotherapy versus radiotherapy alone for recurrent/progressive glioblastoma: A systematic review. Journal of Neuro-Oncology, 152(3), 419–428.

5. Razlansari, M., Jafarinejad, S., Rahdar, A., Shirvaliloo, M., Arshad, R., & others. (2023). Development and classification of RNA aptamers for therapeutic purposes: An updated review with emphasis on cancer. Molecular and Cellular Biochemistry, 478(7), 1573–1598.*

Dr. Milad Shirvaliloo’s pioneering research in epigenetics and nanomedicine bridges molecular science with clinical application, driving innovations in cancer and pulmonary disease diagnostics and therapies. His work advances precision medicine and fosters global scientific collaboration, contributing to more effective, personalized healthcare solutions.

Sukanta Nath | Cancer Research | Outstanding Scientist Award

Dr. Sukanta Nath | Cancer Research | Outstanding Scientist Award 

Research Scientist at Atal Bihari Vajpayee Regional Cancer Centre ,India

Dr. Sukanta Nath is a distinguished Research Scientist with over 13 years of experience in biotechnology and cancer research. He holds a Ph.D. in Biotechnology from Gauhati University and currently serves at the Atal Bihari Vajpayee Regional Cancer Centre, Tripura. His career spans prestigious institutions including the Indian Institute of Science, Aurigene Discovery Technologies, and Agility Diagnostics. Dr. Nath has contributed significantly to the fields of molecular biology, virology, and oncology through numerous research projects, publications, and conference presentations. He has a strong background in molecular profiling, gene expression, and cancer diagnostics, particularly Acute Myeloid Leukaemia. His dedication to advancing healthcare is also evident through his contributions to nursing intervention research in oral cancer patients. Recognized with multiple awards for research excellence and presentation, Dr. Nath continues to serve as a mentor, reviewer, and active participant in scientific forums. His work reflects a blend of academic rigor and translational medical relevance.

🔹 Professional Profile

🏆Strengths for the Award

  1. Extensive Research Experience:
    Dr. Sukanta Nath possesses more than 13 years of experience in cancer research, molecular biology, and biotechnology. His academic and professional journey through reputed institutions like IISc Bangalore, Aurigene Discovery Technologies, and Agility Diagnostics highlights a consistent dedication to scientific advancement.

  2. Specialization in Molecular Oncology:
    His Ph.D. research focused on molecular profiling in Acute Myeloid Leukemia (AML), specifically targeting key mutations such as FLT3, NPM1, and PML-RARα. This demonstrates a deep understanding of molecular cancer diagnostics.

  3. Translational and Clinical Research:
    Dr. Nath has successfully translated laboratory research into clinical practice, particularly in studies involving oral cancer patient recovery, anxiety, and fatigue. His interdisciplinary focus bridges molecular mechanisms with patient-centered care.

  4. Recognized Contributions and Awards:
    He has received notable recognitions, including the Best Researcher Award from ScienceFather and awards for oral and poster presentations at national academic events. He was also awarded the DBT-BCIL Fellowship, demonstrating government-level acknowledgment of his potential.

  5. Relevant and Recent Publications:
    His 2025 publication on high-risk HPV genotypes among women in North–East India contributes to both regional public health and global understanding of cervical cancer prevention, reflecting timely and impactful research.

  6. Mentorship and Scientific Involvement:
    Dr. Nath actively serves as a peer reviewer and mentor, supporting the broader scientific community and demonstrating a commitment to research ethics and academic development.

🎓 Education

Dr. Sukanta Nath pursued his Ph.D. in Biotechnology from Gauhati University, where he conducted impactful research on molecular profiling in Acute Myeloid Leukaemia. Prior to that, he completed his Master of Science in Biotechnology from Utkal University, where he gained foundational expertise in molecular biology and immunological techniques. His undergraduate studies were in the biological sciences, with a B.Sc. in Botany, Zoology, and Physiology from the University of Calcutta. He received his higher secondary and school education under the Tripura Board of Secondary Education. Throughout his academic journey, Dr. Nath has consistently focused on life sciences, biotechnology, and biomedical research, building a robust academic foundation that supports his ongoing professional contributions. His education was complemented by several technical training programs and hands-on experiences that prepared him for roles in molecular diagnostics, cancer biology, and clinical research.

💼 Experience

Dr. Sukanta Nath has a rich professional background with over 13 years in research and diagnostics. He is currently a Research Scientist at the Atal Bihari Vajpayee Regional Cancer Centre in Tripura, focusing on oncology and postoperative care studies. Previously, he worked as a Research Associate at the College of Fisheries, Central Agricultural University, Tripura. His industry experience includes a key role as Molecular Scientist and Quality Manager at Agility Diagnostics, Delhi. At Gauhati University, he served both as a Ph.D. scholar and Junior Research Fellow, contributing to leukemia-focused molecular studies. Dr. Nath also held a Research Associate role at Aurigene Discovery Technologies (Dr. Reddy’s Lab) and served as a Project Assistant at IISc Bangalore in a CSIR-funded cancer genomics project. His career reflects a synergy between academic research and clinical application, marked by multidisciplinary collaborations, laboratory expertise, and contributions to cancer diagnostics, infectious disease monitoring, and healthcare quality assurance.

🏆 Awards and Honors

Dr. Sukanta Nath has been honored with several prestigious awards recognizing his excellence in research and presentation. He received the Best Researcher Award from ScienceFather during the 23rd International Research Data Analysis Excellence Awards. His scientific presentations have also been lauded: he secured First Place for Best Oral Presentation at the 1st NE Hematology Tutorial (2016) and Third Place for Best Poster at the National Seminar on Climate-Smart Aquaculture and Fisheries (2019). Dr. Nath was also selected for a Biotech Consortium India Limited (BCIL) Fellowship under the DBT, Government of India. He has been acknowledged for his performance by Aurigene Discovery Technologies and has received a Certificate of Appreciation for his contributions. Furthermore, he served as a peer reviewer for journals such as Patient Preference and Adherence. His commitment to research, education, and scientific excellence is evident through these national and international recognitions.

🔬 Research Focus on Cancer Research

Dr. Sukanta Nath’s research centers on molecular biology, cancer genomics, and clinical oncology, with special emphasis on Acute Myeloid Leukaemia (AML). His Ph.D. and subsequent work have involved extensive molecular profiling of genetic mutations such as NPM1, FLT3, AML1/ETO, and PML/RARα, which are crucial in leukemia diagnostics and prognosis. At the Regional Cancer Centre in Tripura, he has pioneered studies addressing post-surgical recovery, anxiety, and fatigue in oral cancer patients, highlighting his translational focus on improving patient outcomes. His interests extend into virology, where he has worked on hepatitis genotyping and viral diagnostics. Dr. Nath also contributes to public health through studies on COVID-19 prevalence and KAP (knowledge, attitude, practice) among cancer patients. His multidisciplinary approach bridges bench-side molecular research with bedside clinical care, making his work relevant for both academic advancements and real-world medical applications. His contributions are marked by high-impact publications and collaborative studies.

📚 Publications Top Notes

Title:Molecular epidemiology and genotype distribution of genital high-risk human papillomavirus among women in North–East India

Journal:Egyptian Journal of Medical Human Genetics

Year:2025

Summary:
This study focuses on the molecular epidemiology of high-risk genital human papillomavirus (HPV) among women in North–East India. It aims to identify the prevalent HPV genotypes in the region and understand their distribution patterns. Using molecular diagnostic methods, the research highlights the frequency of various high-risk HPV strains, contributing to better-informed screening and prevention strategies, including HPV vaccination programs in the area. The study plays a significant role in regional public health planning for cervical cancer prevention.

📌 Conclusion

Dr. Sukanta Nath exemplifies a dedicated and versatile researcher whose work spans both the molecular and clinical domains of biomedical science. His 13+ years of experience reflect a blend of academic precision, research innovation, and patient-centered study design. With a Ph.D. focused on genetic profiling in leukemia and extensive research into oral cancer care, Dr. Nath has significantly contributed to the understanding and treatment of critical health conditions. His collaborations with reputed institutions and involvement in both diagnostics and therapeutic research underscore his comprehensive expertise. Beyond technical acumen, his mentorship, peer review contributions, and public health studies show a commitment to improving healthcare at multiple levels. Recognized through awards and fellowships, his contributions continue to impact oncology, virology, and molecular diagnostics. As he progresses in his career, Dr. Nath stands as a role model for translational researchers aiming to bridge the gap between laboratory science and clinical excellence.

Dr. Laura Cerchia | translational cancer research | Best Researcher Award

Dr. Laura Cerchia | translational cancer research | Best Researcher Award

PI, Group Leader at Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore”, National Research Council, Italy

Dr. Laura Cerchia is a leading researcher in cancer-targeting RNA aptamer technologies, serving as Group Leader at the Institute of Endotypes in Oncology, Metabolism and Immunology (CNR, Italy). She pioneered the cell-SELEX method, widely adopted across international labs, and developed multiple aptamers targeting tumor biomarkers such as EGFR, AXL, and PDGFRβ. These aptamers have significant applications in imaging, immunotherapy, and targeted drug delivery, with some now used globally in advanced nanomedicine platforms. Author of over 90 peer-reviewed publications with an H-index of 36, she also holds four international patents. Dr. Cerchia has received numerous grants and serves on several national and international scientific committees, including Horizon Europe’s PHIRE project. Her expertise is recognized through roles as evaluator, editorial board member, and scientific advisor. Her work bridges fundamental research and therapeutic innovation, making her a key figure in translational oncology and a strong candidate for the Best Researcher Award.

Professional Profile 

Scopus Profile
ORCID Profile 

Education

Dr. Laura Cerchia earned her PhD in Biochemical Sciences, building a strong academic foundation in molecular biology and biochemistry. Her educational background equipped her with expertise in RNA biology, molecular diagnostics, and therapeutic development. Her advanced training allowed her to explore the structural and functional aspects of nucleic acids, which later became central to her innovative work in aptamer development. During her academic years, she developed an early interest in translational research, which led her to specialize in the design of synthetic oligonucleotides for medical applications. Her doctoral and postdoctoral studies laid the groundwork for her pioneering approach in using aptamers for targeted cancer therapy. Her education not only deepened her scientific knowledge but also instilled a critical problem-solving mindset that continues to influence her research directions. Her scholarly path reflects a combination of academic rigor and innovative thinking, forming the basis for her future contributions to biomedical science.

Professional Experience

Dr. Laura Cerchia is currently Group Leader at the Institute of Endotypes in Oncology, Metabolism and Immunology “G. Salvatore” (IEOMI) within the National Research Council of Italy (CNR). Her professional journey has been marked by impactful roles in both scientific leadership and collaborative research. She developed the widely used cell-SELEX procedure and generated several clinically relevant RNA aptamers targeting key tumor markers. Beyond laboratory research, Dr. Cerchia serves on editorial boards of journals such as Scientific Reports and Molecules, and holds evaluative and advisory roles in national and international research bodies, including the Horizon Europe-funded PHIRE project. Her career reflects a balance of scientific innovation, project management, and institutional leadership. She has successfully secured multiple research grants, built interdisciplinary teams, and advanced new diagnostic and therapeutic approaches. Her professional experience showcases her ability to lead complex research initiatives and influence the broader scientific and clinical communities.

Research Interest

Dr. Cerchia’s research focuses on the development of nuclease-resistant RNA aptamers for cancer theranostics, therapeutics, and targeted drug delivery. She is especially interested in the use of aptamers as precision tools for recognizing and binding specific biomarkers in tumors, such as EGFR, AXL, and PDGFRβ. Her work involves designing aptamers that can be used for in vitro and in vivo imaging, antagonistic therapies, and as carriers for chemotherapeutics, small molecule inhibitors, siRNAs, or photosensitizers. Her innovations in cell-SELEX have enabled the selection of highly specific aptamers against aggressive cancer types like glioblastoma, NSCLC, and triple-negative breast cancer (TNBC). She is also exploring the potential of aptamers in immunotherapy, including their integration with nanomedicine platforms. Her interest lies in translating basic molecular discoveries into clinical applications, with a strong focus on personalized medicine. Overall, her research aims to bridge gaps between molecular biology, oncology, and therapeutic delivery systems.

Award and Honor

Dr. Laura Cerchia has received multiple national and international recognitions for her contributions to cancer research and aptamer technology. She is the recipient of prestigious research grants and has been invited to serve on scientific evaluation panels, including for the Wellcome Trust (UK), ANR SHAMS, PRIN, and Horizon Europe projects. In 2018, she achieved the National Scientific Qualification, allowing her to function as a Full Professor in general and clinical pathology within Italian universities—an acknowledgment of her academic and professional excellence. She also serves as President and expert evaluator for PRIN 2022 PNRR – ERC Sector LS1, reinforcing her leadership role in shaping national research priorities. Her aptamers are cited and utilized worldwide, further validating the high translational value of her work. In addition to her editorial board positions, these honors demonstrate her broad influence, scientific credibility, and sustained contributions to advancing biomedical research on both national and international levels.

Conclusion

Dr. Laura Cerchia exemplifies the qualities of a world-class biomedical researcher through her pioneering work in RNA aptamer technologies, extensive publication record, and active leadership in the international scientific community. With a robust educational background, decades of impactful professional experience, and deep research expertise, she has made significant contributions to translational cancer therapy. Her innovations have enabled more precise targeting of tumors, enhancing both diagnostic and therapeutic capabilities. Her work has not only influenced academic circles but also spurred technological advances in nanomedicine and drug delivery. The widespread adoption of her aptamers across global research groups attests to the relevance and utility of her discoveries. Coupled with numerous awards, advisory roles, and editorial contributions, her profile reflects excellence, leadership, and a forward-looking vision in biomedical science. Dr. Cerchia’s continued efforts make her a strong candidate for high honors such as the Best Researcher Award and a role model in scientific innovation.

Publications Top Notes

  • Title: A novel therapeutic approach targeting PD-L1 in HNSCC and bone marrow-derived mesenchymal stem cells hampers pro-metastatic features in vitro: perspectives for blocking tumor-stroma communication and signaling
    Authors: Not listed
    Year: 2025

  • Title: A novel CD44-targeting aptamer recognizes chemoresistant mesenchymal stem-like TNBC cells and inhibits tumor growth
    Authors: Not listed
    Year: 2025

  • Title: Preclinical Toxicological Characterization of Porphyrin-Doped Conjugated Polymer Nanoparticles for Photodynamic Therapy
    Authors: Not listed
    Year: 2025

  • Title: Urine-Stable Aptamer-Conjugated Gold Nanorods for the Early Detection of High-Grade Bladder Cancer Residual Disease
    Authors: Not listed
    Year: 2025
    Citations: 1

  • Title: Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids: implications for precision phototherapies
    Authors: Not listed
    Year: 2024
    Citations: 11

  • Title: Ferroptosis in Cancer: Epigenetic Control and Therapeutic Opportunities
    Authors: Not listed
    Year: Not available
    Citations: 6

  • Title: Subtype Transdifferentiation in Human Cancer: The Power of Tissue Plasticity in Tumor Progression
    Authors: Not listed
    Year: Not available
    Citations: 2

  • Title: Correction to: Bispecific aptamer-decorated and light-triggered nanoparticles targeting tumor and stromal cells in breast cancer derived organoids
    Authors: Not listed
    Year: 2024

  • Title: Correction to: Selective Photo-Assisted Eradication of Triple-Negative Breast Cancer Cells through Aptamer Decoration of Doped Conjugated Polymer Nanoparticles
    Authors: Not listed
    Year: 2022
    Citations: 1

Mohd Farhan | Cancer Biology | Excellence in Research Award

Assoc. Prof. Dr. Mohd Farhan | Cancer Biology | Excellence in Research Award 

Associate Professor, King Faisal University, Saudi Arabia

Dr. Mohd Farhan is an accomplished Associate Professor at King Faisal University, Saudi Arabia 🇸🇦. With a strong background in biochemistry, he is dedicated to exploring the molecular mechanisms behind the anticancer properties of plant-derived nutraceuticals. His extensive research contributes significantly to the field of cancer research and DNA repair 🌱.

Publication Profile

ORCID

Education:

Dr. Farhan earned his PhD in Biochemistry from Aligarh Muslim University, India 🇮🇳. His academic journey has equipped him with in-depth knowledge and skills that enhance his research endeavors.

Experience:

Dr. Farhan has held positions at King Faisal University since 2018, initially serving as an Assistant Professor before advancing to his current role as Associate Professor in Basic Sciences. His dedication to teaching and research has made him a respected figure in his field 🎓.

Research Focus:

His research primarily revolves around cancer research, DNA repair, and the health benefits of plant polyphenols. Dr. Farhan aims to uncover the potential of plant-derived compounds in cancer prevention and treatment, making significant strides in the field of nutritional biochemistry 🔬.

Awards and Honours:

Dr. Farhan has received various accolades for his contributions to science and education. His work is recognized not only in academic circles but also in broader research communities, reflecting his impact on the field 🏆.

Publication Top Notes:

Dr. Farhan has an impressive list of publications, including:

The Potential Role of Polyphenol Supplementation in Preventing and Managing Depression: A Review of Current Research (2024) in Life

Clinical Trial Findings and Drug Development Challenges for Curcumin in Infectious Disease Prevention and Treatment (2024) in Life

Crops and People: The Dangers and Potential Benefits of Pesticides (2024) in Cogent Food and Agriculture

Cytotoxic Activity of the Red Grape Polyphenol Resveratrol Against Human Prostate Cancer Cells: A Molecular Mechanism Mediated by Mobilization of Nuclear Copper and Generation of Reactive Oxygen Species (2024) in Life

Dietary Polyphenols, Plant Metabolites, and Allergic Disorders: A Comprehensive Review (2024) in Pharmaceuticals

Green Nanobiocatalysts: Enhancing Enzyme Immobilization for Industrial and Biomedical Applications (2024) in PeerJ

 

Chenjing Zhu | Oncology | Best Researcher Award

Dr. Chenjing Zhu | Oncology | Best Researcher Award

Associate professor, Jiangsu Cancer Hospital, China

Cenjing Zhu is a dedicated medical professional specializing in radiation oncology at Jiangsu Cancer Hospital, Nanjing, China. With a strong background in clinical research and cancer treatment, she has made significant contributions to understanding cancer biology and therapeutic strategies. Dr. Zhu has a keen interest in advancing medical science through research, education, and clinical excellence. 🌟💉

Publication Profile

ORCID

Education

Dr. Zhu completed her Bachelor of Medicine (2011-2016) and M.D. (2016-2019) from the West China School of Medicine, Sichuan University, Chengdu, China. Her academic journey in the field of medicine has paved the way for her expertise in oncology and cancer research. 🎓📚

Experience

Since 2019, Dr. Zhu has been a part of the Department of Radiation Oncology at Jiangsu Cancer Hospital, where she contributes to both clinical care and scientific research. Her leadership in cancer research and clinical innovation is well-recognized within the medical community. 🏥💼

Research Focus

Dr. Zhu’s research primarily revolves around cancer therapeutics, focusing on the AXL receptor tyrosine kinase as an anti-cancer approach, psychological distress in cancer patients, and innovative diagnostic techniques in oncology. She is particularly interested in tumor microenvironment modulation and the application of advanced imaging techniques in cancer treatment. 🔬🧬

Awards and Honors

Throughout her career, Dr. Zhu has been invited to present her work at prestigious international conferences, including the World Congress on Advances in Oncology and the International Symposium on Molecular Medicine. Her research excellence has garnered recognition and invitations to prominent platforms for cancer research and molecular medicine. 🏆🌍

Publication Top Notes

Zhu’s influential article on AXL receptor tyrosine kinase as a promising anti-cancer approach, Molecular Cancer 2019, has reshaped clinical strategies, cited extensively.

Her 2020 study on dual MET/AXL inhibitors in gastric carcinoma, published in MedComm, offers groundbreaking insights into tumor microenvironment modulation.

Zhu’s 2024 research in BMC Psychol on psychological distress in Chinese cancer patients demonstrates the importance of mental health during cancer treatment.

Her 2024 review of circulating microRNAs as diagnostic biomarkers for cervical cancer in Discov Oncol continues to shape diagnostic research in oncology